Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on May 9, 2007
J Am Soc Nephrol 18: 1922-1927, 2007
© 2007 American Society of Nephrology
doi: 10.1681/ASN.2006121388

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2006121388v1
18/6/1922    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garcia-Garcia, G.
Right arrow Articles by Tonelli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garcia-Garcia, G.
Right arrow Articles by Tonelli, M.
Related Collections
Right arrowRelated Article

Epidemiology and Outcomes

Survival among Patients with Kidney Failure in Jalisco, Mexico

Guillermo Garcia-Garcia*, Gregorio Briseño-Rentería*, Victor H. Luquín-Arellan*, Zhiwei Gao{dagger}, John Gill{ddagger} and Marcello Tonelli{dagger}

* Nephrology Service, Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico; {dagger} Department of Medicine, University of Alberta, Alberta, Edmonton, Canada; and {ddagger} Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

Address correspondence to: Dr. Guillermo Garcia-Garcia, Hospital Civil de Guadalajara, Hospital 278, 44280 Guadalajara, Jalisco, Mexico. Phone: +52-33-3614-7456, ext. 310; Fax: +52-33-3817-3514; garciagg{at}prodigy.net.mx

Received for publication December 20, 2006. Accepted for publication March 19, 2007.

ESRD is a serious public health problem in the state of Jalisco, Mexico. This study evaluated mortality in poor patients who initiated dialysis at the Jalisco Health Secretariat, compared with Hispanic patients without medical insurance who initiated dialysis in the United States. All patients who received a diagnosis with ESRD between February 1 and December 31, 2003, were studied prospectively at a single institution that provides care to the poor of Jalisco. Data from an American national dialysis registry and Cox proportional hazards models were used to compare the adjusted survival among Jalisco patients with that of a contemporaneous group of incident Hispanic patients who did not have Medicare or private insurance cover and who initiated peritoneal dialysis in the United States. Of 274 consecutive patients who presented with a clinical diagnosis of ESRD in Jalisco, mean estimated GFR at dialysis initiation was very low (3.9 ± 2.4 ml/min per 1.73 m2), and <10% were previously known to a nephrologist. Of the 274 patients, 102 (37.2%) did not initiate dialysis therapy, 71 (69.6%) of whom died during follow-up. The majority (n = 49) of such deaths occurred in-hospital before dialysis initiation. Of 172 patients who initiated dialysis, 36 (20.9%) died within the first 90 d of renal replacement therapy. An additional 31 (18.0%) patients died during a median follow-up of 186 d. When all 274 Jalisco patients who presented with ESRD were considered, survival was 49.6% at the end of follow-up. Unadjusted mortality rates among those who survived at least 90 d after dialysis initiation were 19.2 (95% confidence interval [CI] 13.5 to 27.3) and 5.9 (95% CI 4.6 to 7.7) per 100 patient-years in Jalisco and American patients, respectively. After adjustment, the risk for death remained nearly three-fold higher in Jalisco patients (hazard ratio 2.7; 95% CI 1.5 to 4.7). Poor patients with kidney failure in Jalisco have very advanced disease at the time of first nephrologic contact and have exceedingly high rates of mortality after dialysis initiation. Our findings demonstrate a tremendous opportunity to reduce morbidity and mortality from kidney disease in Jalisco and perhaps other regions of Mexico.


Related Article

Renal Replacement Therapy in the Developing World: Are We on the Right Track, or Should There Be a New Paradigm?
Ricardo Correa-Rotter
J. Am. Soc. Nephrol. 2007 18: 1635-1636. [Full Text] [PDF]






HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP